GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Accounts Payable & Accrued Expense

PaxMedica (PaxMedica) Accounts Payable & Accrued Expense : $1.20 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Accounts Payable & Accrued Expense?

PaxMedica's quarterly accounts payable & accrued expense declined from Sep. 2023 ($1.69 Mil) to Dec. 2023 ($1.01 Mil) but then increased from Dec. 2023 ($1.01 Mil) to Mar. 2024 ($1.20 Mil).

PaxMedica's annual accounts payable & accrued expense declined from Dec. 2021 ($1.42 Mil) to Dec. 2022 ($1.26 Mil) and declined from Dec. 2022 ($1.26 Mil) to Dec. 2023 ($1.01 Mil).


PaxMedica Accounts Payable & Accrued Expense Historical Data

The historical data trend for PaxMedica's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Accounts Payable & Accrued Expense Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 0.12 1.08 1.42 1.26 1.01

PaxMedica Quarterly Data
Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.71 1.69 1.01 1.20

PaxMedica Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


PaxMedica (PaxMedica) Business Description

Industry
Traded in Other Exchanges
N/A
Address
303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Executives
Zachary Rome director, officer: Chief Operating Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman director, officer: Chief Executive Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle director 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho director 22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough officer: Chief Medical Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon officer: Chief Financial Officer 2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748